Verve Therapeutics, Inc. Analysis
| Analyst Ratings |
|
Average Target Price
|
44.78
|
|
Average Rating
|
4.10
|
|
# Strong Buys
|
5
|
|
# Buys
|
2
|
|
# Holds
|
2
|
|
# Sells
|
1
|
|
# Strong Sells
|
0
|
| Quarterly Earnings History |
| Quarter |
EPS Estimate |
EPS Actual |
EPS Difference |
Surprise Percent |
|
2023-03-31
|
-0.76
|
0.00
|
0.76
|
100.00%
|
|
2022-12-31
|
-0.75
|
0.00
|
0.75
|
100.00%
|
|
2022-09-30
|
-0.74
|
-0.79
|
-0.05
|
-6.76%
|
|
2022-06-30
|
-0.65
|
-0.84
|
-0.19
|
-29.23%
|
|
2022-03-31
|
-0.66
|
-0.62
|
0.04
|
6.06%
|
|
2021-12-31
|
-0.55
|
-0.65
|
-0.10
|
-18.18%
|
|
2021-09-30
|
-0.45
|
-0.47
|
-0.02
|
-4.44%
|
|
2021-06-30
|
-0.49
|
-6.66
|
-6.17
|
-1259.18%
|
| Annual Earnings History |
| Fiscal Year End |
EPS |
|
2022-12-31
|
-2.25
|
|
2021-12-31
|
-8.40
|
|
2020-12-31
|
-4.99
|
|
2019-12-31
|
-2.92
|